BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 32007320)

  • 1. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
    Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
    Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
    Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
    Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
    Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
    Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer.
    Zhang Y; Roth JA; Yu H; Ye Y; Xie K; Zhao H; Chang DW; Huang M; Li H; Qu J; Wu X
    Carcinogenesis; 2019 Jul; 40(5):643-650. PubMed ID: 30428030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
    Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
    Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
    Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P
    Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
    Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
    Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
    Zhang W; Zhang Q; Che L; Xie Z; Cai X; Gong L; Li Z; Liu D; Liu S
    BMC Cancer; 2022 Mar; 22(1):299. PubMed ID: 35313857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
    Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
    Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.
    Zhang ZJ; Song XG; Xie L; Wang KY; Tang YY; Yu M; Feng XD; Song XR
    Exp Biol Med (Maywood); 2020 Oct; 245(16):1428-1436. PubMed ID: 32741216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
    Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
    Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
    Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
    J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Jin X; Chen Y; Chen H; Fei S; Chen D; Cai X; Liu L; Lin B; Su H; Zhao L; Su M; Pan H; Shen L; Xie D; Xie C
    Clin Cancer Res; 2017 Sep; 23(17):5311-5319. PubMed ID: 28606918
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).
    Liao J; Shen J; Leng Q; Qin M; Zhan M; Jiang F
    Thorac Cancer; 2020 Mar; 11(3):762-768. PubMed ID: 31994346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer.
    Dong X; Chang M; Song X; Ding S; Xie L; Song X
    Thorac Cancer; 2021 Feb; 12(4):539-548. PubMed ID: 33372399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.